jcp conference-coverage

Conference Coverage

Bendamustine-Rituximab Followed by Rituximab ± Lenalidomide for Mantle Cell Lymphoma

12/10/2022

Mitchell R Smith, MD, and colleagues presented data at the 64th ASH Annual Meeting and Exposition on whether progression-free survival is prolonged by the addition of bortezomib to bendamustine-rituximab induction and/or by the addition of...

Mitchell R Smith, MD, and...

12/10/2022

Journal of Clinical Pathways

Conference Coverage

A 12-Gene Signature Accurately Predicts Progression From Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma

12/10/2022

Craig Ostroff ;

Speaking at the 64th ASH Annual Meeting and Exposition, Fumou Sun, PhD, and colleagues discussed a 12-gene score that demonstrated noticeable accuracy in predicting 10-year progression to multiple myeloma in a limited population of patients...

Speaking at the 64th ASH Annual...

12/10/2022

Journal of Clinical Pathways

Conference Coverage

Real-world Outcomes of ASCT in Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma

12/10/2022

Craig Ostroff ;

Julie Cote, MD, and colleagues discuss real-world outcomes of patients treated with autologous stem cell transplant as part of their initial multiple myeloma therapy during their presentation at the 64th ASH Annual Meeting and Exposition.

Julie Cote, MD, and colleagues...

12/10/2022

Journal of Clinical Pathways

Conference Coverage

HER2-Low Breast Cancer in the National Cancer Database

12/09/2022

Katie Herman ;

Daniel Peiffer, MD, PhD, and colleagues discuss a retrospective cohort study comparing clinical characteristics and demographics of HER2-0 vs HER2-low cases.

Daniel Peiffer, MD, PhD, and...

12/09/2022

Journal of Clinical Pathways

Videos

The Impact of HER2-low Status on Prognosis in Hormone Receptor-Positive Metastatic Breast Cancer Treated With a Targeted Therapy Plus Endocrine Therapy

12/08/2022

Jason Mouabbi, MD, discusses his presentation from the 2022 San Antonio Breast Cancer Symposium on survival outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer, finding that HER2-low status may not...

Jason Mouabbi, MD, discusses his...

12/08/2022

Journal of Clinical Pathways

Conference Coverage

HER2-Positive Metastatic Breast Cancer Treatment Patterns in Patients Who Have Received at Least Two Lines of Therapy

12/07/2022

Katie Herman ;

Della Varghese, PharmD, PhD, and colleagues presented a poster at the 2022 San Antonio Breast Cancer Symposium studying second-line (2L) treatment patterns and outcomes among HER2+ metastatic breast cancer (mBC) patients in the United States.

Della Varghese, PharmD, PhD, and...

12/07/2022

Journal of Clinical Pathways

Conference Coverage

Clinical and Pathological Differences in Breast Cancer Patients With HER2-low and Other Cancer Subtypes

12/07/2022

Katie Herman ;

Andre Mattar, MD, PhD, and colleagues presented their study at the 2022 San Antonio Breast Cancer Symposium demonstrating significant differences between HER2-low and other cancer subtypes in breast cancer patients.

Andre Mattar, MD, PhD, and...

12/07/2022

Journal of Clinical Pathways

Dr Joshua Richter, Associate Professor of Medicine, Tisch Cancer Institute

Videos

Analyzing the Effect of Immune Therapies on Infection in Patients With Multiple Myeloma

12/05/2022

Dr Joshua Richter, associate professor of medicine at Tisch Cancer Institute, discusses his presentation on the effects of immune therapies on infection in patients with multiple myeloma.

Dr Joshua Richter, associate...

12/05/2022

Journal of Clinical Pathways

OCPC: In Session

Highlights of the 2022 Clinical Pathways Benchmark Survey

12/05/2022

Winston Wong , PharmD;

Winston Wong, PharmD, Editor-in-Chief, presents the highlights of the 2022 Clinical Pathways Benchmark Survey results, as presented as part of the Oncology Clinical Pathways Congress in Boston in October.

Winston Wong, PharmD,...

12/05/2022

Journal of Clinical Pathways

Videos

Telehealth Utilization in Clinical Trial Research and Participation

10/27/2022

Matthew Lunning, DO, FACP, discusses the expansion of telehealth during the “COVID era,” highlighting the importance of face-to-face encounters between patients and health care providers, and suggesting ways to successfully meet this demand...

Matthew Lunning, DO, FACP,...

10/27/2022

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

2024 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Update: Impact on NSCLC Landscape

11/15/2024

The updated 2024 NCCN Guidelines® recommend broad genomic testing and the need for multidisciplinary care to accurately diagnose and treat non-small cell lung cancer. View this special report to learn more.

The updated 2024 NCCN...

11/15/2024

Journal of Clinical Pathways

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Conference Coverage

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products